15.19
-0.13 (-0.85%)
| Previous Close | 15.32 |
| Open | 15.26 |
| Volume | 310,268 |
| Avg. Volume (3M) | 757,438 |
| Market Cap | 5,393,847,296 |
| Price / Earnings (Forward) | 13.39 |
| Price / Sales | 1.06 |
| Price / Book | 0.810 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | -7.50% |
| Operating Margin (TTM) | -5.36% |
| Diluted EPS (TTM) | -1.02 |
| Quarterly Revenue Growth (YOY) | 3.50% |
| Total Debt/Equity (MRQ) | 75.07% |
| Current Ratio (MRQ) | 1.56 |
| Operating Cash Flow (TTM) | 166.00 M |
| Levered Free Cash Flow (TTM) | 69.00 M |
| Return on Assets (TTM) | 0.61% |
| Return on Equity (TTM) | -5.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Bausch + Lomb Corporation | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.63 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 88.13% |
| % Held by Institutions | 10.97% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 17.00 (Evercore ISI Group, 11.92%) | Buy |
| Median | 16.00 (5.33%) | |
| Low | 13.00 (Morgan Stanley, -14.42%) | Hold |
| Average | 15.40 (1.38%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 14.02 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 07 Oct 2025 | 17.00 (11.92%) | Buy | 14.66 |
| Goldman Sachs | 01 Oct 2025 | 16.00 (5.33%) | Hold | 14.67 |
| Morgan Stanley | 01 Aug 2025 | 13.00 (-14.42%) | Hold | 13.50 |
| HC Wainwright & Co. | 31 Jul 2025 | 16.00 (5.33%) | Buy | 13.63 |
| Wells Fargo | 31 Jul 2025 | 15.00 (-1.25%) | Hold | 13.63 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |